Three trends of the adjustment of the basic medicine catalogue of the health and family planning commission!

Source: at the beginning of 2015-01-31, the Commission of health and family planning organizes some major projects to entrust relevant scientific research institutions for research, and the published scientific research projects can provide a glimpse of the next policy direction of the Commission In order to strengthen the policy research work related to the drug policy and the basic drug system, on January 29, the health and Family Planning Commission announced the public bidding for the 2015 project research plan From the bidding subject, generic drugs will receive more benefits 1、 In the future, the first topic entrusted by the national health and Family Planning Commission for cancer treatment and life-saving drugs or the national health and Family Planning Commission is about the issue of parody The theme of the topic is the international drug parody policy and the actual case study The purpose of the study is to put forward the advantages and disadvantages of the implementation of the policy of Parody in China and the countermeasures; and to put forward specific policy recommendations to promote the development and production of drugs in China This means that in the future, the life-saving drugs for treating cancer and other diseases are expected to be imitated by domestic pharmaceutical companies Domestic pharmaceutical companies should prepare quickly, roll up their sleeves and select which drugs can be imitated, and speed up the research and development process as soon as possible Last year, Lu Yong, who was convicted of purchasing Indian generic drugs for leukaemia treatment in India, caused a stir in domestic public opinion More than 300 white blood patients jointly applied for innocence The most discussed issue in various media is the issue of India's parody Whether China can parody is also widely raised Now policy is finally expected to usher in loosening 2、 The second topic of generic and original research drug big PK is the clinical comprehensive evaluation of some basic drugs: part of a class of vaccines, hepatitis B antiviral drugs The purpose of this study is to make a comprehensive clinical evaluation of some basic drugs (some first-class vaccines, hepatitis B antiviral drugs) and finally draw a conclusion The content of comparison is part of class I vaccine and hepatitis B antiviral drugs For class I vaccine comparison, it should mainly be the impact of domestic vaccine events in the past two years The frequent vaccine events in China have been controversial for domestic vaccines This time, it is necessary to re evaluate the quality of vaccine market For hepatitis B antiviral, China is a big country of liver disease, especially hepatitis B Although the supplementary catalogue of many provinces includes hepatitis B antiviral drugs, it is not included in the national basic drug catalogue at present From the perspective of research content, on the one hand, this may mean that hepatitis B antiviral drugs are expected to be included in the national basic drug catalog in the future On the other hand, more importantly, the country will carry out the clinical comparison of the quality of imported and domestic drugs There is a huge difference between generic drugs and original research drugs When bidding, both sides are divided into different quality levels Relying on quality advantages, the original research drugs can win the bid at a high price Domestic pharmaceutical enterprises believe that the quality of domestic generic drugs has been greatly improved after the development of these years, and the quality level of foreign original research drugs has been comparable However, in many bidding processes The voice of the bid office is very weak This time, the PK of the clinical effects of domestic generic drugs and the original research drugs means that the health and Family Planning Commission has finally begun to face up to the quality comparison between them If the quality of domestic generic drugs can pass the standard, then in the future bidding, domestic generic drugs are expected to be proud and get rid of the bad quality hat Because this subject is presided over by the health and Family Planning Commission, its significance is even greater If the scope of this comparison is further expanded, it is likely that generic drugs will enjoy greater benefits For the result, cypress blue maintains certain optimism Because of the comparison of hepatitis B antiviral drugs, this does not enter the base drug catalog in a wide range If it is a selected variety that enters the national base drug catalog, cypress blue may be quite worried about the results In the case of big price reduction in the bidding of basic drugs in various provinces, there are not many high-quality bid winners, and the comparison result may be that the generic pharmaceutical enterprises can no longer turn over the poor quality At the same time, it can be expected that regardless of the results, it will have a great impact on the bidding of base drugs in the future Enterprises should pay close attention to it 3、 Rare diseases are also expected to enter the basic drug catalogue One of the tasks entrusted by the basic drug catalogue office is the establishment of foreign common rare diseases and drug databases Last year, the ice bucket challenge was very lively After the excitement, the rare patients group was also included in the public opinion field of vision (the health and Family Planning Commission now really attaches great importance to the guidance of public opinion, and pays close attention to the public voice, which is praised here) As you all know, in the important work arrangement of 2015 health and Family Planning Commission shared with you a few days ago, the problem of base drug catalog evaluation was mentioned According to the analysis of the insiders, this is the rhythm of base drug catalog to be adjusted Does the research on this subject entrusted by the base drug catalog office mean that rare diseases will be included in the future base drug catalog supplement? 4、 The further expansion of the scope of decoction pieces of traditional Chinese medicine is still entrusted by the directory of basic drugs The selection and analysis of the commonly used decoction pieces of traditional Chinese medicine are standardized The purpose is to study the occurrence of the drug prescription composition and clinical use of the commonly used decoction pieces, and to put forward the policy recommendations on the scope of commonly used decoction pieces and the standardization of commonly used decoction pieces More pieces of traditional Chinese medicine will be included in the list of basic drugs, which is good 5、 The adjustment of base drugs in 2015 is the most important From the perspective of this issue, 7 of the 10 scientific research topics have been entrusted by the base drug catalogue office, in addition to the two aspects detailed above (sabran thinks that this may be the two directions for supplement) It also involves the proportion of basic drugs used in primary medical institutions Now the proportion of basic drugs used is determined by each province, and may be unified nationwide in the future In addition, the base drug catalogue also commissioned evidence-based medicine and pharmacoeconomics research on base drugs, which is a noteworthy trend In the future, quality and cost performance will become an important bidding direction in the bidding of base drugs However, this kind of direction needs to be further liked We need to see how the health and Family Planning Commission implements it After all, quality priority is also the requirement of the basic drug system However, if we look at the price reduction war in the bidding of each province, good policy guidance needs to see the specific implementation strategy In this regard, cypress blue can only keep a cautious and optimistic attitude 2015 research project commissioned by the Department of drug administration Author: situ Yangming